Special Issue

Anticancer Nanomedicine: Recent Advances

Message from the Guest Editor

Cancer continues to be one of the main causes of death worldwide. A concerted effort in research is urgently needed to decrease the health and socioeconomic impact of cancer. Nowadays, it is known that nanomedicine can contribute to the development of advanced and more efficient therapeutics, helping to fight cancer by providing improved outcomes in terms of toxicity and overall survival. Recent advances regarding the role of the tumor microenvironment and the immune system in cancer progression and formation of metastasis have prompted the development of new nanomedicines specifically designed to target cell populations other than cancer cells, as well as the development of combinatory treatments to provide a holistic approach. In parallel, nanomedicine can contribute to the development of innovative diagnosis modalities for the early detection of cancer and followup, as well as more advanced nanotheranostics. This Special Issue aims to incorporate a summary of up-todate articles to provide a comprehensive overview of the most recent advances in cancer nanomedicine.

Guest Editor

Dr. Maria de la Fuente

Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), CIBERONC, 15706 Santiago de Compostela, Spain

Deadline for manuscript submissions

closed (31 March 2021)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/50867

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

